Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 124 Show results per page	View Search Criteria \| Help With Results


1.		A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				18 and over				Pharmaceutical / Industry				ML18527 NCT00121836

Last Modified: 11/7/2007 First Published: 11/1/2002


2.		Phase II/III Randomized Study of Capecitabine Versus Vinorelbine in Women With Metastatic Breast Cancer Previously Treated With Taxanes With or Without Anthracyclines

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Other				EORTC-10001 EORTC-16001O, IDBBC-EORTC-10001, NCT00049660

Last Modified: 12/10/2007 First Published: 11/4/2005


3.		Phase II/III Randomized Study of Vinorelbine, Cisplatin, and Continuous Hyperfractionated Accelerated Radiotherapy (CHART) Versus CHART Alone in Patients With Stage I-III Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				Over 18				Other				MRC-LU23 EU-20535, EU-INCH-20535, EudraCT-2004-004438-15, NCT00253591

Last Modified: 11/21/2008 First Published: 9/1/1994


4.		Phase III Randomized Study of Adjuvant Vinorelbine and Cisplatin Versus No Adjuvant Chemotherapy in Patients With Completely Resected Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				CAN-NCIC-BR10 CLB-9795, E-JBR10, SWOG-JBR10, GW-565/040, NCI-V94-0492, NCT00002583, BR10, JBR10

Last Modified: 6/1/1999


5.		Phase III Randomized Study of Epirubicin/Vinorelbine vs Epirubicin Alone for Advanced Breast Cancer (Summary Last Modified 06/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 75								DAN-DBCG-94-03 EU-95008

Last Modified: 1/22/2008


6.		Phase III Randomized Study of TAX/CBDCA vs VNB/CDDP for Stage IV and Selected Stage IIIB non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				SWOG-9509

Last Modified: 8/1/1997


7.		Phase III Randomized Study of High-Dose vs Low-Dose Docetaxel vs Standard Chemotherapy with Vinorelbine or Ifosfamide for Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy (Summary Last Modified 08/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				MSKCC-95088 RP-56976-TAX-320, NCI-V96-0830

Last Modified: 7/26/2007


8.		Phase III Randomized Study of Adjuvant Chemotherapy Following Curative Resection for non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 75				Other				FRE-IALT EU-96010, NCT00002823

Last Modified: 9/1/1999


9.		Phase III Randomized Study of Adjuvant Fluorouracil/Epirubicin/Cyclophosphamide vs Epirubicin/Vinorelbine in Women with High-Risk Node-Positive Breast Cancer (Summary Last Modified 09/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				under 65								FRE-FNCLCC-GFEA-09 EU-96015, FRE-GFEA-09

Last Modified: 8/3/2007 First Published: 2/1/1998


10.		Phase III Randomized Study of Surgery With or Without Preoperative Chemotherapy in Patients With Resectable Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Any age				Other				MRC-LU22 EORTC-08012, EU-97016, ISRCTN25582437, NCT00003159

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute